Sarepta therapeutics announces positive clinical results from momentum, a phase 2 clinical trial of srp-5051 in patients with duchenne muscular dystrophy amenable to skipping exon 51

-- results from the multiple - ascending dose trial demonstrate proof-of-concept for srp-5051 and support continued dose escalation -- -- at a total dose exposure approximately 10x lower than eteplirsen, srp-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater dystrophin production with no negative renal or other laboratory findings --
SRPT Ratings Summary
SRPT Quant Ranking